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Abstract
Vascular Endothelial Growth Factor (VEGF) is a major regulator of angiogenesis. VEGF expression is up regulated in response
to micro-environmental cues related to poor blood supply such as hypoxia. However, regulation of VEGF expression in
cancer cells is not limited to the stress response due to increased volume of the tumor mass. Lipid mediators in particular
arachidonic acid-derived prostaglandin (PG)E2 are regulators of VEGF expression and angiogenesis in colon cancer. In
addition, increased osmolarity that is generated during colonic water absorption and feces consolidation seems to activate
colon cancer cells and promote PGE2 generation. Such physiological stimulation may provide signaling for cancer
promotion. Here we investigated the effect of exposure to a hypertonic medium, to emulate colonic environment, on VEGF
production by colon cancer cells. The role of concomitant PGE2 generation and MAPK activation was addressed by specific
pharmacological inhibition. Human colon cancer cell line Caco-2 exposed to a hypertonic environment responded with
marked VEGF and PGE2 production. VEGF production was inhibited by selective inhibitors of ERK 1/2 and p38 MAPK
pathways. To address the regulatory role of PGE2 on VEGF production, Caco-2 cells were treated with cPLA2 (ATK) and COX-
2 (NS-398) inhibitors, that completely block PGE2 generation. The Caco-2 cells were also treated with a non selective PGE2
receptor antagonist. Each treatment significantly increased the hypertonic stress-induced VEGF production. Moreover,
addition of PGE2 or selective EP2 receptor agonist to activated Caco-2 cells inhibited VEGF production. The autocrine
inhibitory role for PGE2 appears to be selective to hypertonic environment since VEGF production induced by exposure to
CoCl2 was decreased by inhibition of concomitant PGE2 generation. Our results indicated that hypertonicity stimulates VEGF
production in colon cancer cell lines. Also PGE2 plays an inhibitory role on VEGF production by Caco-2 cells exposed to
hyperosmotic stress through EP2 activation.
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Introduction
Formation of new blood vessels from pre-existing vasculature is a
central process in the development of most tumors especially solid
ones. This process is called angiogenesis and is regulated by the
balance of negative and positive biochemical signals. The newly
formed blood vessels are responsible for supplying oxygen and
nutrients for the growing tumor mass and a route for dissemination
of metastatic cancerous cells. VEGF is the most prominent positive
regulator of angiogenesis due to its ability to recruit endothelial cells
to hypoxic sites and to stimulate the proliferation of this cellular
type, promoting the differentiation of vascular structures [1]. VEGF
expression correlates positively with negative outcome in cancer
patients. In colon cancer, expression of VEGF correlates with
increased metastatic potential [2], while expression of its receptor is
a marker of shorter post-operative survival [3].
VEGF expression is up regulated in response to micro-
environmental cues related to poor blood supply such as hypoxia
[4], acidosis [5] and low nutrient levels [6]. In tumors, decreased
levels of O2 leads to HIF-1a stabilization, a subunit of the
transcriptional factor HIF-1, and subsequent transcriptional
activation of genes presenting a hypoxia-responsive element
(HRE) in their promoters, such as VEGF. However, VEGF
expression regulation in cancer cells is not limited to the stress
response due to the increased volume of the tumor mass. Several
other factors have been shown to induce VEGF such as reactive
oxygen species [7–9], growth factors [10,11], cytokines [12], and
lipid mediators [13–16]. Arachidonic acid-derived prostaglandin
(PG)E2 is a major regulator of VEGF expression and angiogenesis
in several different cancer types and in colon cancer in particular.
Exogenous PGE2 induces HIF-1a stabilization [13] and VEGF
expression [17] in colon cancer cell lines. VEGF and COX-2
expression and tumor angiogenesis are positively correlated in
colon cancer samples [18–20].
However, hypoxia is not the only external stress stimulus which
activates cellular responses in colon cancer. The continuously
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cancerous epithelial cells to a myriad of stimuli. Such physiological
stimulation may provide signaling for cancer promotion. In fact,
increased osmolarity that is generated during the process of
colonic water absorption and feces consolidation [21–23] appears
to activate colon cancer cells and promote COX-2 expression and
PGE2 generation but does not activate normal intestinal cells [24].
Our aim in this study was to determine the effect of hypertonic
stress on VEGF production by Caco-2 colon cancer cell line. The
potential role of autocrine PGE2 and MAPK signaling pathways in
the modulation of VEGF generation was also analyzed.
Methods
Reagents
Sodium chloride (NaCl) was obtained from Sigma Chemical
Co. (St. Louis, MO) and dissolved in sterile water for a stock
solution at 2 M concentration. The iPLA2 inhibitor, Bromoenol
lactone (BEL), the cPLA2/iPLA2 inhibitor, Arachidonyl Trifluor-
omethyl Ketone (ATK), and Prostaglandin E2 were purchased
from Cayman Chemical Co. (Ann Arbor, MI) and diluted in
ethanol accordingly to manufacturer’s instructions. The inhibitors
for COX-2, NS-398 (Cayman); p38, SB202190; JNK, SP600125;
MEK1/2, U0126 (all from BIOMOL, Plymouth Meeting, PA)
were diluted in DMSO (Sigma). Monoclonal antibodies for
immunoblot assays were anti-COX-2 IgG mouse (clone 33) from
BD Transduction Laboratories and anti-GAPDH (clone 6C5) IgG
mouse from Santa Cruz Biotechnology (Santa Cruz, CA), diluted
at 0.003 mg/mL. The goat HRP-linked secondary antibody anti-
mouse IgG from Santa Cruz Biotechnology was used at 0.1 mg/
mL.
Cell culture and treatments
Caco-2 (ATCC HTB-37, gift of Dr. Jose ´ Morgado Dı ´az,
Instituto Nacional de Ca ˆncer, Brazil) cell line was maintained in
Dulbecco Modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 44 mM NaHCO3,1 m M
NaH2PO4.H2O, 1 mM sodium pyruvate, 10 mM HEPES,
MEM vitamins solution, MEM essential and non-essential amino
acids solution, 2 mM L-glutamine, 55 mM b-mercaptoethanol,
100 U/mL penicillin, and 100 mg/mL streptomycin (all cell
culture reagents from Invitrogen). IEC-6 cell line (Rio de Janeiro
Cell Bank, Brazil) was maintained in DMEM supplemented with
5% FBS and 100 U/mL penicillin, and 100 mg/mL streptomycin.
Cells were maintained in culture flasks (cell growth surface area
25, 75 and 150 cm
2). Cells were collected by 0.25% trypsin and
0.38 g/L EDTA in HBSS without Ca
++ and Mg
++ and 5610
5
cells/well were plated in 6-well flat-bottom plates (area of
9.03 cm
2/well, Techno Plastic Products, Switzerland). 1.9 mL of
fresh supplemented DMEM culture medium was added to culture
wells with or without pharmacological inhibitors and cells were
incubated for 15 min (30 min for MAP kinases inhibitors) at 37uC.
All cells received the same amount of vehicle, therefore, the final
concentration was below 0.1% of DMSO or ethanol and did not
modify cell activation. Cells were stimulated with the addition of
0–100 mL of 2 M NaCl solution. DMEM was added to the well to
complete final volume of 2 mL. Final osmolarity of the medium
after addition of 100 mM NaCl was approximately 540 mOsm as
compared to 367 mOsm of isosmotic medium. Medium osmolar-
ity was empirically determined by freezing method using an
osmometer (Advanced Instruments Inc., Norwood, MA). To
minimize variation in the kinetic experiments the total time in
culture after plating was the same for every time point analyzed.
Determination of PGE2 and VEGF on supernatants
The PGE2 production by Caco-2 cell line was determined by
EIA in culture supernatant accordingly to manufacturer’s
instructions (Cayman) and as described before [25]. Briefly,
culture medium was collected 24 h after cellular activation by
hypertonic stress and centrifuged at 2506g for 5 min to remove
floating cells and frozen at 270uC. PGE2 levels were assayed using
a monoclonal antibody PGE2 EIA Kit. After development plate
was read at 405 nm in a plate reader (Spectra Max 190, Molecular
Devices, Sunnyvale, CA). The VEGF production by Caco-2 cell
line was determined by ELISA in culture supernatant accordingly
to manufacturer’s instructions (R&D Systems, UK). Briefly,
culture medium was collected 24 h after cellular activation by
hypertonic stress and centrifuged at 2506g for 5 min to remove
floating cells and frozen at 270uC. VEGF levels were assayed
using a human VEGF DuoSet (R&D Systems, UK). After
development plate was read at 450 nm in a plate reader (Spectra
Max 190, Molecular Devices, Sunnyvale, CA).
Immunoblot analysis
Cells were collected with a cell scraper (COSTAR) and 100 mL
of 10% SDS was added per well of the 6-well cell culture plate.
100 mLo f2 6loading buffer (1.4 M b-mercaptoethanol, 184 mM
Tris base, 80 mM Bromophenol blue, 3% glycerol, 8% SDS,
pH 6.8) was added to the cell lysate. Cellular lysates were
immediately heated at 100uC for 5 minutes prior to sonication at
30% of amplitude and 30 J of energy in a high intensity ultra-sonic
processor. Samples were resolved by electrophoresis on a SDS-
PAGE 10% polyacrylamide gel at 29 mA/gel for 1 h. Separated
proteins were transferred to nitrocellulose membranes (Santa
Cruz) and blocked in 5% non-fat dry milk in 16 TBS (Tris
10 mM; NaCl 150 mM pH 7,4) for 12 h for COX-2 labeling, or
for 2 h for all other antibodies at room temperature. After
washing, membranes were incubated with primary antibodies
diluted in TTBS (TBS with 0.2% Tween 20) and 0.05% sodium
azide for 2 hours at room temperature for COX-2 or 12 hours at
4uC for other antibodies. After secondary labeling with HRP-
linked anti-IgG antibodies, proteins were analyzed using ECL
Western Blotting Analysis System (Amersham Biosciences).
Statistical analysis
Data are expressed as mean 6 standard error of the mean (SEM)
of experiments performed in triplicates. Graphs and western blots
shown are representative of at least three independent experiments.
Multiple comparisons among groups were performed by one-way
ANOVA followed by Bonferroni’s or Dunnett’s test (Prism version
4.03, Graphpad Software, Inc. La Jolla, CA). The symbols
+ and *
represent p values,0.05 when compared to control non-stimulated
group or hypertonic stress/CoCl2-stimulated group respectively.
Results
Hypertonic stress induces VEGF production by Caco-2
and PGE2 modulates the angiogenic factor production in
this environmental stress
Hypertonic stress stimulates the VEGF production by Caco-2
after 24 hours of activation (Figure 1A) following the same dose
response and time course (data not shown) of PGE2 generation
under the same stimulatory conditions [24]. As PGE2 has been
described to play a role in angiogenesis and VEGF production we
determined whether PGE2 was regulating VEGF production by
Caco-2 during the stimulation with hypertonic medium. Inhibiton
of PGE2 production by treatment with cPLA2 (ATK) (Figure 1B)
Autocrine PGE2 Role in Hypertonic VEGF Production
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production. This phenomenon was reversed by the addition of
PGE2 to the cell culture medium (Figure 1D) indicating a specific
role for PGE2.
To verify whether inhibition of VEGF production by Caco-2
stimulated with hypertonic stress was a consequence of PGE2
action and not a consequence of the nonespecific action of
pharmacological drugs used in the experiments, we performed the
same experiment in HCT116, a colon cancer cell line that does
not express COX-2 and produces no detectable levels of PGE2
under hypertonic stress. We did not observe any changes in the
VEGF production, excluding the possibility of interference of the
pharmacological inhibitors (Figures 1E and F). Those results
showed that PGE2 produced by Caco-2 activated by hypertonic
stress has an autocrine inhibitory action on VEGF production.
EP2 receptor plays a role in the regulation of VEGF
production through PGE2 in Caco-2 stimulated with
hypertonic stress
To determine what is the mechanism of action of PGE2 in the
regulation of VEGF production in hypertonic stress, Caco-2 cells
were activated with hypertonic medium during 24 hours and treated
with AH6809, an EP receptor antagonist. We verified the inhibition
of EP receptor signaling caused an increase of VEGF production
(Figure 2A). Then, to identify which specific receptor is involved in
this phenomenon Caco-2 were stimulated with hypertonic medium
and treated with ATK and EP receptors agonists. The cPLA2
inhibitor (ATK) removed the interference of PGE2 produced by
colon cancer cells and EP receptors were activated only by
exogenously added agonists. Accordingly, figure 2B shows that
treatment with ATK increases VEGF production and when PGE2 or
Figure 1. Endogenous PGE2 modulates VEGF production by hypertonic stress-stimulated Caco-2 cells. (A) Caco-2 cells were stimulated
with 10–100 mM of NaCl during 24 h before VEGF production analysis. VEGF production was determined by ELISA in supernatants of Caco-2 cells
stimulated with hypertonic stress (100 mM NaCl) during 24 h after pre-treatment with inhibitors of cPLA2, ATK (B); COX-2, NS-398 (C) or PGE2 (D).
HCT116 cells were stimulated with 100 mM of NaCl during 24 h after pre-treatment with inhibitors of cPLA2, ATK (E); COX-2, NS-398 (F). +,*p,0.05,
to non-stimulated cells or stimulated cells, respectively. ** p,0.05, when compared to NS-398-treated cells. Graph bars show means 6 SEM from
triplicate samples.
doi:10.1371/journal.pone.0025193.g001
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medium this effect was reversed, reinforcing that EP receptor
activation has an inhibitory effect on VEGF production. Increase in
VEGF production by inhibition of endogenous PGE2 was also
reversed by butaprost, a specific EP2 receptor agonist (Figure 2B).
Activation with EP1, 17-phenyl-trino-PGE2,o rE P 3 ,S u l p r o s t o n e ,
agonists had no effect on increased VEGF production. Since EP4
expression seems to be absent inCaco-2 cells[26], our results indicate
that endogenous PGE2 modulates VEGF production induced by
hypertonic stress through activation of EP2.
EP2 is a rhodopsin type receptor coupled to Gs and mediates
increases in camp [27]. Thus we tested if PKA played a role in
PGE2 effects mediated through EP2 during hypertonic stress.
Inhibition of PKA by H-89 increased VEGF production by Caco-
2 cells exposed to hypertonic medium (Figure 2C). Reinforcing the
potential inhibitory pathway involving PGE2-EP2-cAMP-PKA.
Role of endocrine PGE2 on CoCl2-induced VEGF
production
We also verified whether PGE2 had a role in the regulation of
VEGF production under a standard simulatory condition. To
activate the Hypoxia-Induced Factor (HIF) pathway and simulate
hypoxia, Caco-2 cells were activated with CoCl2. After 24 hours of
stimulation with CoCl2, Caco-2 presented marked production of
PGE2 (Figure 3A) and increased expression of COX-2 (Figure 3B).
Further experiments were performed after additon of 1 mM of
CoCl2 to the medium after 24 hours of activation. Moreover,
CoCl2-stimulated PGE2 generation is dependent on COX-2 as it
was completely inhibited by NS-398 (Figure 3C).
Similar to hypertonic stress stimulation, CoCl2-activated cell
also produced VEGF (Figure 3D). However, autocrine PGE2
appears to have an opposite effect in this condition since NS-398
treatment inhibited VEGF production (Figure 3E). Those results
indicate that PGE2 has a stimulatory autocrine role on VEGF
production in CoCl2 activation.
Role of MAPKs in VEGF production by Caco-2 cells
To determine if the VEGF production was differentially
regulated in Caco-2 cells beyond the potential autocrine role of
PGE2, we turned to the identification of MAPK pathways involved.
Since we have shown before a role for ERK 1/2, JNK and p38 in
PGE2 generation [24] and to avoid the potential problem this may
pose to interpret the results, experiments were performed in the
presence of 1 mM of NS-398. Pharmacological inhibition of ERK
1/2 and p38 pathways indicated a common role in activation by
either hypertonic stress or CoCl2 (Figures 4A and B). JNK role was
more restricted, as SP 600125 markedly inhibited VEGF produc-
tion induced by CoCl2 activation while it did not affect VEGF
production induced by hypertonic stress (Figures 4A and B).
Discussion
The role of PGE2 in cancer development is usually described as
an autocrine factor capable of modulating many aspects of the
Figure 2. EP2 receptor plays a role in endogenous PGE2 regulation of VEGF production by Caco-2 stimulated with hypertonic stress.
(A) Caco-2 cells were stimulated by hypertonic stress (100 mM NaCl) during 24 h after pre-treatment with EP and DP receptors antagonist, AH 6809
(A); with inhibitor of cPLA2, ATK (10 mM); PGE2; EP receptors agonist, 16,16-dimethyl Prostaglandin E2; EP1 and EP3 receptors agonist, 17-phenyl trinor
Prostaglandin E2; EP2 receptor agonist, butaprost and EP3 receptor agonist, sulprostone (B); or with PKA inhibitor, H-89. PGE2 and its analogs were
used at 0.1 mM. VEGF production was determined by ELISA in supernatants of Caco-2 cells. +,*p,0.05, when compared to non-stimulated cells or
stimulated cells, respectively. ** p,0.05, when compared to ATK-treated cells. Graph bars show means 6 SEM from triplicate samples.
doi:10.1371/journal.pone.0025193.g002
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during 24 h before PGE2 and VEGF production (A and D, respectively) and COX-2 protein expression (B) analysis. PGE2 and VEGF production by Caco-
2 cells stimulated with 1 mM of CoCl2 during 24 h after pre-treatment with inhibitor of COX-2, NS-398 (C and E, respectively). VEGF production by
Caco-2 cells stimulated with 0.1–1 mM of CoCl2 during 24 h (D). PGE2 and VEGF production were determined by ELISA in supernatants of Caco-2
cells. COX-2 and GAPDH expression in cell pellets was analyzed by Western blotting. +,*p,0.05, when compared to non-stimulated cells or
stimulated cells, respectively. Graph bars show means 6 SEM from triplicate samples.
doi:10.1371/journal.pone.0025193.g003
Figure 4. Role of MAPKs in VEGF production by Caco-2 cells. Inhibitors of JNK, SP600125; p38, SB202190; and MEK 1/2, U0126 were added
before stimulation with hypertonic stress (100 mM NaCl) (A) or 1 mM CoCl2 (B) for 24 h. Caco-2 cells were pretreated with 1 mM of NS-398 to prevent
endogenous PGE2 production in all samples. VEGF production was determined by ELISA in supernatants of Caco-2 cells. +,*p,0.05, when compared
to non-stimulated cells or stimulated cells, respectively. Graph bars show means 6 SEM from triplicate samples.
doi:10.1371/journal.pone.0025193.g004
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PGE2 has been shown to increase proliferation, metastatic
capacity and production of pro-angiogenic factors [17,30,31].
However, such studies usually lack information on the stimuli that
will drive the arachidonic acid cascade and ultimately PGE2
generation beyond induced expression of COX-2. We have
recently demonstrated that a hyperosmotic milieu can induce
COX-2 expression and PGE2 generation in Caco-2 colon cancer
cells [24]. Most importantly, hyperosmolarity can trigger the
limiting step in PGE2 generation by activating cPLA2-a and
inducing the release of free arachidonic acid. Normal intestinal
epithelial cells showed no production of PGE2 under the same
hyperosmotic stimulus. Having identified a relevant physiological
stimulus for colon cancer cells, we investigated the effect of
hypertonic medium on the production of the major pro-
angiogenic factor, VEGF, and the potential autocrine influence
of PGE2.
Exposure of Caco-2 cells to hypertonic medium led to a
significant production of VEGF. As demonstrated before this
VEGF production occurred in parallel with the PGE2 generation.
PGE2 is described as a potent inducer of VEGF based on
experiments where COX-2 overexpression increased VEGF
production by colon and breast cancer cell lines. Furthermore,
this VEGF production was inhibited by selective COX-2
inhibitors. We therefore sought to investigate the autocrine
influence of PGE2 generation on Caco-2 cells stimulated by
hypertonic medium. Suprisingly, inhibition of either cPLA2 or
COX-2, by ATK or NS-398 respectively, further increased the
production of VEGF. This effect could be attributed to inhibition
of PGE2 generation as restoration of PGE2 levels by exogenous
addition reverted VEGF production to its original levels in ATK
treated Caco-2 cells. HCT116 cells can also be activated by
hypertonic medium to produce VEGF. However, HCT116 cells
neither express COX-2 nor produce PGE2 [31] despite the cells
being activated or not. Thus, the lack of effect of ATK and NS-
398 on HCT116 excludes any potential off target effects of these
inhibitors [32].
PGE2 acts on a group of G-protein-coupled receptors (GPCRs).
There are four GPCRs responding to PGE2 designated subtypes
EP1, EP2, EP3 and EP4, leading to distinct signaling pathway and
overall biological effect [27]. To determine the dependence of
PGE2 autocrine effects on EP signaling, we used a nonspecific
antagonist of all four EP receptors, AH 6809. The treatment with
AH 6809 mimicked the effect of inhibition of VEGF production
by PGE2, indicating that PGE2 signals through its plasma
membrane receptors to down regulate VEGF production induced
by hypertonic medium. The particular subtype involved appears
to be EP2 as its selective agonist, Butaprost, is able to fully
substitute for PGE2. On the opposite, neither EP1 nor EP3
agonists treatments presented the inhibitory effect on VEGF
production. EP2 seems to couple with increased cAMP levels and
subsequent activation of PKA, as inhibition of PKA by H-89
reproduces the effects of inhibiting PGE2 generation or action. It is
important to note that the experiments were performed with PGE2
and its analogs in concentrations that were compatible with the
endogenously produced levels. Effects in VEGF production by
colon cancer cells have been ascribed to PGE2 using concentra-
tions of up to 100 mM [13] what far exceed the amount of PGE2
actually needed to activate its receptors [27] or what is produced
in the tumoral mass [33].
It has been shown the activation of EP2-cAMP-PKA-GSK-3
signaling pathway leads to decrease of beta-catenin phosphoryla-
tion, allowing its translocation and activation of Tcf/Lef
dependent-transcription (for a review, see [34]) of genes involved
in cancer, such as COX-2 and VEGF. However, in our model of
hypertonic stress, EP2 signaling pathway activation causes
repression of VEGF production. To better understand the
regulation of this pathway in the hypertonic stress we investigated
the role of GSK-3in this activation with the use of SB216763, a
competitive GSK-3 a and b inhibitor (50–5000 nM, data not
shown). The treatment increased the VEGF production, indicating
that the inhibitory effect of EP2 on the angiogenic factor
production is not dependent on this kinase. One possibility for
the distinct effect of EP2 activation in hypertonic stress is that this
regulation is occurring through cAMP. Some studies have been
shown cAMP can inhibit the production of cytokines by inhibiting
Ras-dependent signals by PKA, inactivating MEK/ERK signaling
or by blocking phosphorylation of p38 MAPK [35–37]. As ERK/
p38 MAPK pathway is involved in our model inducing VEGF
production, such findings could be indicative of the mechanism by
which EP2 signaling is blocking VEGF production in hypertonic
stress.
To determine whether the inhibitory role of PGE2 may be
extended to other stimuli, we used CoCl2 to induce HIF-1a
stabilization and mimick the response to hypoxia [13]. As shown
for hypertonic stimulation, CoCl2 induced PGE2 generation was
dependent on COX-2. The PGE2 generation was also paralleled
by VEGF production. Induction of VEGF production by CoCl2
has been shown before in human fibroblasts [38], lung cancer cell
line [39], retina epithelium [40], glioma cell lines [41], prostate
cancer cell lines [42] and in astrocytes [43], however there was no
attempt to investigate the potential production of PGE2 or its
autocrine effects. Inhibition of COX-2 inhibited VEGF produc-
tion induced by CoCl2, indicating a stimulatory role for PGE2 and
that the autocrine effect of PGE2 is dependent on the type of
stimuli used.
Hypertonic medium induces activation of several MAP kinases
that may be involved in regulating VEGF expression [24]. Since
these MAP kinases are also involved in stimulating cPLA2-a
activity and production of PGE2, we eliminated the inhibitory
effect of PGE2 before attempting to analyse their role on VEGF
production. Caco-2 cells activated by hypertonic medium in the
presence of NS-398 clearly show a marked dependence on p38
and less so on ERK 1/2 to produce VEGF. CoCl2-induced VEGF
production by Caco-2 cells showed similar sensitivity profile to
MAP kinase inhibitors with the exception of a marked reduction
by the JNK inhibitor. The distinct roles for JNK pathway indicate
that differences in hypertonic medium and CoCl2-induced
production of VEGF go beyond sensitivity to autocrine inhibitory
effects of PGE2. It is currently under investigation if such signaling
differences may be responsible for the distinct effects of PGE2 on
each type of stimuli.
One of the hallmarks in the current model for the regulation of
angiogenesis in the tumor mass, particularly in colon cancer, is the
regulation of endothelial cell function by the cancerous cells.
Accordingly, the role of PGE2 in angiogenesis is limited to an
autocrine stimulation of pro-angiogenic factors production by the
tumor cell. Although interesting, this model neither comprises the
potential external stimuli involved in COX-2 expression and
VEGF production nor situations where the cell expressing COX-2
and producing PGE2 is other than the cancer cell. For instance,
ectopic growth of HCT116 and HT29, cells that do not express
COX-2 or produce PGE2, is dependent on COX-2 expression by
endothelial and stromal cells [44]. COX-2 expression in mouse
models of familial adenomatous polyposis, Min [33,44] and
Apc
D716 [45] mice, is restricted to stromal and interstitial cells.
Differences in JNK dependency and autocrine PGE2 inhibitory
Autocrine PGE2 Role in Hypertonic VEGF Production
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a clear indication on how the model must also take into account
that these cells are exposed to different microenvironmental
stimuli.
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